Kymera Therapeutics
KYMR
176 hedge funds and large institutions have $3.27B invested in Kymera Therapeutics in 2024 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 56 increasing their positions, 64 reducing their positions, and 16 closing their positions.
125% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 16
62% more capital invested
Capital invested by funds: $2.01B → $3.27B (+$1.26B)
12% more funds holding
Funds holding: 157 → 176 (+19)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
1.53% less ownership
Funds ownership: 109.83% → 108.3% (-1.5%)
13% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 64
27% less call options, than puts
Call options by funds: $2.82M | Put options by funds: $3.88M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$48.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$27M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$22.1M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$19.9M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$89.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$39.7M |
| 3 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$20M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$11.4M |
| 5 |
Goldman Sachs
New York
|
-$10.5M |
KYMR Hedge Fund Activity: Q3 2024 in Review
176 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q3 2024, worth a combined $3.27B — up 62% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new KYMR positions and 16 closed out — a net gain of 20 holders — while 56 added to existing stakes and 64 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $48.8M. The largest seller was Artal Group, exiting entirely with an estimated $89.7M sold.
- 176 institutional investors held Kymera Therapeutics (KYMR) as of Q3 2024, up from 157 in Q2 2024.
- Funds reported $3.27B of Kymera Therapeutics stock for Q3 2024, up 62% quarter-over-quarter.
- 36 funds opened new Kymera Therapeutics positions in Q3 2024 and 16 closed out, a net change of +20 holders.
- The largest Kymera Therapeutics buyer in Q3 2024 was Driehaus Capital Management, an estimated $48.8M added.
- The largest Kymera Therapeutics seller in Q3 2024 was Artal Group, an estimated $89.7M sold.
Based on aggregated 13F filings for Q3 2024.